LABELS · b22cd858-906b-4d8c-9925-24a5b7e16665

OSVYRTI

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-07-07
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating OSVYRTI in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with OSVYRTI in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ]. WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating OSVYRTI in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with OSVYRTI in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 , 5.1 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE OSVYRTI is a RANK ligand (RANKL) inhibitor indicated for: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture OSVYRTI is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis OSVYRTI is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis OSVYRTI is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer OSVYRTI is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer OSVYRTI is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

Full extracted label fields

application numbers

BLA761424

boxed warning exact

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating OSVYRTI in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with OSVYRTI in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ]. WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating OSVYRTI in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with OSVYRTI in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 , 5.1 )

brand names

OSVYRTI

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f3be096-5100-4d0e-b765-481bbb2672e1

generic names

DENOSUMAB-DESU

b22cd858-906b-4d8c-9925-24a5b7e16665

indications and usage exact

1 INDICATIONS AND USAGE OSVYRTI is a RANK ligand (RANKL) inhibitor indicated for: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture OSVYRTI is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis OSVYRTI is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis OSVYRTI is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer OSVYRTI is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer OSVYRTI is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Accord BioPharma Inc.

matched search terms

cancer

package ndcs

69448-021-63

product ndcs

69448-021

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

2746871
2746878

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 357
end exclusive: true
exact text: 1 INDICATIONS AND USAGE OSVYRTI is a RANK ligand (RANKL) inhibitor indicated for: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 0

current approval status

not_reconciled

duplicate text group

dup-ec949fffe55f7aab76a8

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-8b915bf681fba0138c23

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

end: 76
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 32

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 157
end exclusive: true
exact text: 1 INDICATIONS AND USAGE OSVYRTI is a RANK ligand (RANKL) inhibitor indicated for: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 )
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · positive indication candidate

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 438
end exclusive: true
exact text: 1 INDICATIONS AND USAGE OSVYRTI is a RANK ligand (RANKL) inhibitor indicated for: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastat
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 0

current approval status

not_reconciled

duplicate text group

dup-6863dd9c5e7ae591e8fc

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-6ad143208da8b0e52dc6

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

end: 76
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 32

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 238
end exclusive: true
exact text: to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 )
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 158

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 3 · unclassified context

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 528
end exclusive: true
exact text: NK ligand (RANKL) inhibitor indicated for: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiv
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 39

current approval status

not_reconciled

duplicate text group

dup-a452de3aadff12cbd493

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-e0aee92d75c67e039e03

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 328
end exclusive: true
exact text: of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 )
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 239

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 664
end exclusive: true
exact text: gh risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 129

current approval status

not_reconciled

duplicate text group

dup-a378ad3e82cbea5a713a

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-408e6b11769fad9de0bf

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

end: 76
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 32

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 464
end exclusive: true
exact text: to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 )
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 329

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 5 · positive indication candidate

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 794
end exclusive: true
exact text: osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture OSVYRTI is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined a
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 265

current approval status

not_reconciled

duplicate text group

dup-cb8f1c440d6b9f3f14b8

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-1a148274d9b55ba61368

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

end: 76
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 32

qualifier mentions

context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
575
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start
532

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 594
end exclusive: true
exact text: to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 465

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 6 · positive indication candidate

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1157
end exclusive: true
exact text: ndrogen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture OSVYRTI is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men wi
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 395

current approval status

not_reconciled

duplicate text group

dup-e5cd4dc2a764e33faffc

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-97d9ceb3b1fa14988bda

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

end: 697
end exclusive: true
exact text: is indicated
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 685

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 957
end exclusive: true
exact text: 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture OSVYRTI is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 595

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1311
end exclusive: true
exact text: at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis OSVYRTI is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteo
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 758

current approval status

not_reconciled

duplicate text group

dup-f6039ed1dd3716849514

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-4d304865939e7578c3b4

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1111
end exclusive: true
exact text: In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] .
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 958

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1686
end exclusive: true
exact text: rant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis OSVYRTI is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis OSVYRTI is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 912

current approval status

not_reconciled

duplicate text group

dup-ef6baee3b21c232c977d

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-ae822a0e3499a2aa463b

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

end: 1193
end exclusive: true
exact text: is indicated
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 1181

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1486
end exclusive: true
exact text: 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis OSVYRTI is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] .
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 1112

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 9 · positive indication candidate

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2053
end exclusive: true
exact text: ed as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis OSVYRTI is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 1287

current approval status

not_reconciled

duplicate text group

dup-045855c826d29072cae0

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-6f154cd6e49f9bea5544

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

end: 1560
end exclusive: true
exact text: is indicated
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 1548

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1853
end exclusive: true
exact text: 1.3 Treatment of Glucocorticoid-Induced Osteoporosis OSVYRTI is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months.
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 1487

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · risk or warning

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2280
end exclusive: true
exact text: cture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer OSVYRTI is indicated as a treatment to increase bone mass in men at high risk for fracture receiving andro
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 1654

current approval status

not_reconciled

duplicate text group

dup-2a46777d5c8c53bea3f6

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-e94fcc63896281f2c71d

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2080
end exclusive: true
exact text: High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] .
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 1854

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2545
end exclusive: true
exact text: fined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer OSVYRTI is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for B
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 1881

current approval status

not_reconciled

duplicate text group

dup-71d01dba9e01d79efd11

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-d57387091491a485e289

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

end: 2194
end exclusive: true
exact text: is indicated
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 2182

qualifier mentions

context exact
acture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer.
kind
biomarker
polarity
not_inferred
span
end
2344
end exclusive
true
exact text
metastatic prostate cancer
label id
b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start
2318
context exact
acture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
2344
end exclusive
true
exact text
metastatic prostate cancer
label id
b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start
2318

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2345
end exclusive: true
exact text: 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer OSVYRTI is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer.
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 2081

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 12 · unclassified context

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2656
end exclusive: true
exact text: Therapy for Prostate Cancer OSVYRTI is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer OSVYRTI is indicated as a treatment to increase bone mass in women at high risk for fracture recei
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 2146

current approval status

not_reconciled

duplicate text group

dup-f752194c987755285818

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-9a26073ada7674ff2e06

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2456
end exclusive: true
exact text: In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] .
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 2346

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

BLA761424

brand names

OSVYRTI

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2748
end exclusive: true
exact text: racture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer OSVYRTI is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 2257

current approval status

not_reconciled

duplicate text group

dup-a1bd9445d7f03ca90566

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-DESU

ind-span-8df5d287b81ff133e3b2

label id

b22cd858-906b-4d8c-9925-24a5b7e16665

positive predicate support span

end: 2578
end exclusive: true
exact text: is indicated
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 2566

qualifier mentions

context exact
1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer OSVYRTI is indicated as a treatment to increase
kind
stage_or_setting
polarity
not_inferred
span
end
2546
end exclusive
true
exact text
Adjuvant Aromatase Inhibitor Therapy for Br
label id
b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start
2503
context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
kind
stage_or_setting
polarity
not_inferred
span
end
2704
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start
2661

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2748
end exclusive: true
exact text: 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer OSVYRTI is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: b22cd858-906b-4d8c-9925-24a5b7e16665
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b9fef615754a2d9dbb1d03ab3c45b4bdf893b7218063ebfc1bad88e0ec2e9603
start: 2457

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b22cd858-906b-4d8c-9925-24a5b7e16665%22

spl effective date

2026-07-07

spl set id

5f3be096-5100-4d0e-b765-481bbb2672e1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Preserved source evidence · Not medical advice